Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new ...

New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with ...

South Korea’s Alteogen (Kosdaq: 196170) has signed an exclusive licensing agreement with Japanese pharmaceutical company ...

Pfizer plans to invest $1 billion in China by 2030 to support innovation, diagnostics, and the biotech sector, aligning with ...

Viracta Therapeutics has announced a restructuring to focus on its lead oncology candidate, nana-val, targeting EBV-positive ...

The US Food and Drug Administration (FDA) has announced approval of a modification to the Opioid Analgesic Risk Evaluation ...

Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on ...

AlloVir will merge with Kalaris Therapeutics in an all-stock transaction, with Kalaris shareholders holding a 75% stake in ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...

A review has found that complexities and inefficiencies within the UK’s health data infrastructure are hindering the ...

Jazz Pharmaceuticals has reported third-quarter revenue of $1 billion, a 9% increase over the prior year, fueled by strong ...